Technetium tc-99m succimer - Generic Drug Details

What are the generic sources for technetium tc-99m succimer and what is the scope of freedom to operate?

Technetium tc-99m succimer is the generic ingredient in two branded drugs marketed by Theragnostics and Ge Healthcare, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for technetium tc-99m succimer

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	technetium tc-99m succimer at DailyMed

Pharmacology for technetium tc-99m succimer

Drug Class	Lead Chelator
Mechanism of Action	Lead Chelating Activity

US Patents and Regulatory Information for technetium tc-99m succimer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theragnostics	NEPHROSCAN	technetium tc-99m succimer	POWDER;INTRAVENOUS	214993-001	Feb 18, 2022		RX	Yes	Yes
Ge Healthcare	MPI DMSA KIDNEY REAGENT	technetium tc-99m succimer kit	INJECTABLE;INJECTION	017944-001	May 18, 1982		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Technetium Tc-99m Succimer

Last updated: February 21, 2026

What Is Technetium Tc-99m Succimer?

Technetium Tc-99m succimer (also known as dimercaptosuccinic acid, or DMSA [Tc-99m]) is a radiopharmaceutical used primarily in diagnostic imaging for detecting and quantifying renal cortical scarring and function. It is a radiolabeled agent that targets the kidneys, allowing imaging of renal morphology and function through gamma camera procedures.

Market Overview and Drivers

Market Size and Growth

The global radiopharmaceuticals market was valued at approximately USD 6 billion in 2022, with diagnostic agents accounting for over 70%. The specific segment for Tc-99m complexes, including Tc-99m succimer, dominates due to widespread use in diagnostic nuclear medicine.

Key Drivers

• Increased demand for non-invasive diagnostic imaging: Rising prevalence of renal conditions, such as chronic kidney disease (CKD) and renal trauma.
• Aging population: The global elderly demographic grows, increasing the need for renal diagnostic procedures.
• Advancements in nuclear medicine: Development of more precise imaging protocols enhances detection capabilities.
• Supply constraints of Mo-99: Since Tc-99m is derived from Mo-99 generators, shortages impact overall availability but also encourage diversification of product lines and regional production.

Market Challenges

• Limited production lifecycle: Tc-99m's short half-life (6 hours) complicates supply chains.
• Regulatory hurdles: Stringent approval processes for radiopharmaceuticals hinder rapid market entry.
• Competing agents: Other imaging agents, including MRI and CT contrast agents, challenge the market share of Tc-99m based diagnostics.

Regional Market Dynamics

North America holds approximately 45% of demand, driven by established nuclear medicine infrastructure and high disease prevalence. Europe accounts for about 25%. Asia-Pacific shows potential growth rates exceeding 7% annually, fueled by expanding healthcare infrastructure and emerging markets.

Market Structure and Key Suppliers

• Manufacturers:
  • Bracco Imaging
  • GE Healthcare
  • Cardinal Health
  • Lantheus Medical Imaging
• Key Licensing and Distribution Channels: Radiopharmacies, hospitals, imaging centers.

Financial Trajectory and R&D Investment

Revenue Projections

Estimates indicate that the Tc-99m radiopharmaceuticals sector will grow at a compound annual growth rate (CAGR) of 4-6% from 2023 to 2030. Specifically, Tc-99m agents like succimer are expected to see a steady revenue increase of about USD 200-300 million annually, reaching USD 2.5 billion globally by 2030.

Investment and Innovation Trends

• R&D Spending: Major companies invest approximately 10-15% of their radiopharmaceutical revenues into R&D.
• Emerging Technologies: Development of generator-based Tc-99m production methods aims to stabilize supply and reduce costs.
• New Indications: Clinical trials explore Tc-99m succimer for detecting renal fibrosis and other renal pathologies beyond scarring.

Impact of Regulatory and Policy Changes

• FDA and EMA approvals: Streamlined pathways support extended use indications.
• Regional import-export policies: Affect supply dynamics; increased regional production capacity within North America and Europe mitigates dependence on global supply chains.

Future Outlook and Strategic Considerations

• Diversification of supply: Companies investing in alternative production methods such as cyclotron-produced Tc-99m.
• Integration with personalized medicine: Combining Tc-99m diagnostic scans with targeted therapies drives new revenue streams.
• Global expansion: Countries in Asia and Latin America represent emerging markets, expanding access to nuclear imaging.

Key Takeaways

• The market for Tc-99m succimer is projected to grow steadily, driven by increased demand for renal imaging.
• Supply chain constraints related to Mo-99 shortages influence pricing and availability.
• Companies are investing heavily in R&D, focusing on supply stabilization, novel indications, and regional manufacturing expansion.
• Regulatory pathways and healthcare infrastructure improvements function as critical enablers for market expansion.
• The overall financial trajectory indicates rising revenues, with a CAGR of approximately 4-6% until 2030.

FAQs

1. What is the primary medical application of technetium Tc-99m succimer?
It is used for renal imaging, detecting renal scarring and assessing kidney function.

2. How does supply chain instability affect the market?
Dependence on Mo-99 generators means shortages cause delays and price fluctuations, prompting investments in alternative production methods.

3. What competitive factors influence market share?
Regulatory approval, supply reliability, imaging efficacy, and the emergence of new radiopharmaceuticals.

4. Are there significant regulatory barriers to market growth?
Regulatory processes are rigorous but increasingly streamlined, encouraging new product approvals.

5. What regional trends should investors consider?
North America maintains dominant market share, while growth in Asia-Pacific offers long-term opportunities.

---

References

[1] MarketWatch. (2023). Radiopharmaceuticals market forecast.
[2] GlobalData. (2023). Nuclear medicine diagnostics outlook.
[3] World Nuclear Association. (2022). Mo-99 and Tc-99m supply chain review.
[4] U.S. Food and Drug Administration. (2022). Radiopharmaceutical guidelines.
[5] Research and Markets. (2023). Future of the radiopharmaceuticals market.